{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:26:25Z","timestamp":1791851185107,"version":"4.3.4"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T00:00:00Z","timestamp":1273104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The risk of severe infection is a crucial factor in the assessment of the short\u2010term risk:benefit ratio of biologic drugs in rheumatoid arthritis (RA). There is no increase in severe infections in RA patients treated with rituximab (RTX) in controlled trials, but this has not yet been assessed in daily practice. We undertook this study to investigate the occurrence of and risk factors for severe infections in off\u2010trial patients using data from the AutoImmunity and Rituximab (AIR) registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The AIR registry was set up by the French Society of Rheumatology. The charts of patients with severe infections were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the enrolled patients, 1,303 had at least 1 followup visit at 3 months or later, with a mean \u00b1 SD followup period of 1.2 \u00b1 0.8 years (1,629 patient\u2010years). Eighty\u2010two severe infections occurred in 78 patients (5.0 severe infections per 100 patient\u2010years), half of them in the 3 months following the last RTX infusion. Multivariate analysis showed that chronic lung disease and\/or cardiac insufficiency (odds ratio 3.0 [95% confidence interval 1.3\u20137.3], <jats:italic>P<\/jats:italic> = 0.01), extraarticular involvement (odds ratio 2.9 [95% confidence interval 1.3\u20136.7], <jats:italic>P<\/jats:italic> = 0.009), and low IgG level (&lt;6 gm\/liter) before initiation of RTX treatment (odds ratio 4.9 [95% confidence interval 1.6\u201315.2], <jats:italic>P<\/jats:italic> = 0.005) were significantly associated with increased risk of a severe infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The rate of severe infections in current practice is similar to that reported in clinical trials. The risk factors for severe infections include chronic lung and\/or cardiac disease, extraarticular involvement, and low IgG before RTX treatment. This suggests that serum IgG should be checked and the risk:benefit ratio of RTX discussed for patients found to have low levels of IgG.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.27555","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T20:36:49Z","timestamp":1273178209000},"page":"2625-2632","source":"Crossref","is-referenced-by-count":278,"title":["Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry"],"prefix":"10.1002","volume":"62","author":[{"given":"J.\u2010E.","family":"Gottenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cantagrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Flipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Godeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. Le","family":"Lo\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,31]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21778"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062760"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21978"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22808"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21386"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.067660"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22504"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23059"},{"issue":"3","key":"e_1_2_8_13_2","first-page":"76","article-title":"Long term safety of rituximab: follow\u2010up of the RA clinical trials and re\u2010treatment population","volume":"68","author":"Van Vollenhoven RF","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"issue":"3","key":"e_1_2_8_15_2","first-page":"579","article-title":"Rheumatoid factor predicts response to rituximab in a European registry\u2010based cohort: 6\u2010month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA)","volume":"68","author":"Van Vollenhoven RF","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_16_2","first-page":"S305","article-title":"RA patients treated with rituximab: routine care data of the German biologics register RABBIT","volume":"58","author":"Strangfeld A","year":"2008","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70161-5"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.097972"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10529"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23913"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.05.002"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.27555","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.27555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T23:19:30Z","timestamp":1696979970000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.27555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,31]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1002\/art.27555"],"URL":"https:\/\/doi.org\/10.1002\/art.27555","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,31]]}}}